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The complex management of severe burn victims requires an integrative collaboration of multidisciplinary 
specialists in order to ensure quality and excellence in healthcare. This multidisciplinary care has quickly 
led to the integration of cell therapies in clinical care of burn patients. Specific advances in cellular therapy 
together with medical care have allowed for rapid treatment, shorter residence in hospitals and intensive 
care units, shorter durations of mechanical ventilation, lower complications and surgery interventions, 
and decreasing mortality rates. However, naturally fluctuating patient admission rates increase pressure 
toward optimized resource utilization. Besides, European translational developments of cellular therapies 
currently face potentially jeopardizing challenges on the policy front. The aim of the present work is to 
provide key considerations in burn care with focus on architectural and organizational aspects of burn 
centers, management of cellular therapy products, and guidelines in evolving restrictive regulations relative 
to standardized cell therapies. Thus, based on our experience, we present herein integrated management of 
risks and costs for preserving and optimizing clinical care and cellular therapies for patients in dire need.
After the development of cultured cutaneous autografts in 
Boston in the 1980s, our Burn Center was the first in Europe 
to adopt therapeutic cultured cellular product protocols. 
To date, various autologous and allogenic cell therapies are 
elaborated and routinely produced in-house at our Burn 
Center and according to current Good Manufacturing 
Practices (GMP). Thus, our Burn Center has been at the 
forefront of high-quality regenerative therapies for almost 
35 years, and has produced over these three decades an array 
of novel cell therapies in compliance with relevant local and 
European legislations. Cell therapies, both autologous and al-
logenic, have favored structural improvement and functional 
skin regeneration in diverse burn patient populations.1–8
In addition to the surgical and cellular therapeutic level, 
medical advances have also evolved, including restrictive 
fluid management protocols, “minimally restrictive” sedation 
protocols, and nutrition protocols based on careful early en-
teral nutrition focused on protein substitution, mirroring the 
current state-of-the-art in reference Burn Centers. Altogether, 
these advances have allowed for rapid treatment, shorter res-
idence in hospital and intensive care units (ICUs), shorter 
durations of mechanical ventilation, fewer complications and 
surgeries, and decreasing mortality rates in our hospital. As 
a result, massively burned patients with over 90% to 95% of 
TBSA burns may be treated routinely and often survive.9
However, the naturally fluctuating admission rates of burn 
patients have generated increasing pressure toward optimized 
resource utilization and pragmatic operation of Burn Centers. 
We have identified the following risks that may hinder the 
quality of burn care management: on the one hand, the archi-
tectural and organizational setting of a Burn Center that has to 
evolve to maximize the efficiency and quality of individual pa-
tient care; on the other hand, the continuously restrictive and 
constraining regulatory environment for cell therapies, despite 
their demonstrated key roles in severe burn patient care.
The overall goal of the present work is to provide an over-
view and targeted considerations for optimized high-quality 
care provision to severe burn patients. Specifically, we present 
herein practical workflows for optimal operation of a Burn 
Center, GMP production of autologous and allogenic cuta-
neous cellular therapies, as well as evolving specific regulations 
governing integration of such therapies into clinical care. 
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With an aim toward an integrative and specific communica-
tion of current headways and hurdles of severe burn patient 
care, we describe herein key management of risks and costs, 
based on our experience, for preserving and optimizing lives 
of patients in dire need.
OPTIMIZED BURN CENTER ORGANIZATION
Open-Space Unit Design
Consideration of architectural and organizational 
parameters are paramount for optimal establishment and 
operation of specific clinical infrastructures (Figure 1 and 
Table 1). Conventionally, Burn Centers are closed-off units 
with a specific area attributed to burn patients. Over the 
last 15  years, the model of our Burn Center has evolved 
to become an efficient “open” unit located in the general 
ICU of the Hospital (Figure 1), with additional space avail-
able on the respective floors of the Plastic and Pediatric 
Surgery services. Practically, burn patients are prioritized 
for access to five dedicated intensive care beds, which may 
be reallocated to general ICU purposes in case of vacancy. 
Within this “open” unit, strict hygiene protocols specific 
to “closed” burn units have fallen out of favor, without 
leading to (from our experience) increases in the rate of 
infections, as might have been expected. In this design, 
adult and pediatric burn patients share a common clinical 
pathway, which often begins by an initial hospitalization in 
the Burn Unit, before dispatch in Reconstructive Surgery 
and Pediatric Surgery services, respectively.
Burn Center Logistic Workflows
On the main floor, the Burn Center (Figure 1) should com-
prise ICU rooms individually equipped with one patient bed 
and intensive care medical supplies, a workstation, a storage 
area, dedicated air conditioning and ventilation systems, and 
adequate clearance space for the staff. At minimum, one of 
these rooms should be specifically designed as an isolation 
room adapted to accommodate highly sensitive or particu-
larly infected burn patients (eg, multiresistant Pseudomonas 
aeruginosa or Acinetobacter baumannii strains, Ebola or 
SARS-CoV-2 viruses). As such, it comprises an airlock, a 
hydrotherapy bed and sufficient clearance to accommodate 
transformation into an operating theater, while keeping the 
patient confined (Figure 1, isolation room). A  crucial as-
pect in the design and workflows for the Burn Center is the 
air quality, ensuring both patient and staff safety, especially 
during epidemic outbreaks. In such case, laminar-flow type 
ventilation systems can provide fresh air, circulated through 
high efficiency filters, emanating from vents in the ceiling and 
directed vertically toward the floor. The latter is lined with 
corresponding vents that aspirate the air, creating local neg-
ative pressure pockets and limiting propagation of aerosols 
or airborne droplets. These systems are particularly im-
portant in the isolation box, the operating theater, and the 
hydrotherapy room.
The Burn Center should also comprise dedicated operating 
and hydrotherapy rooms for general use by the burn patients. 
Treated patients are showered in the main hydrotherapy 
room, usually under general anesthesia, for dressing changes 
or for scrubbing before going to the operating room (Figure 
1, hydrotherapy room). The main operating room should be 
located right next to the main hydrotherapy room, but should 
not directly communicate with it, for microbiological risk mit-
igation (Figure 1, operation room). This operation room is 
mainly dedicated for burn patients, but can be used occasion-
ally for other surgical interventions, such as organ retrieval for 
transplantation purposes.
Once patients no longer require intensive care, they are 
transferred to the regular floor of the Plastic and Reconstructive 
Surgery service, where a hydrotherapy room is also available 
for common use, in addition to an extra shower integrated 
in a spacious isolation room. As on the ICU floor, nonburn 
patients occupy these quarters in the absence of burn victims.
Multidisciplinary Clinical Care of Burn Victims
Due to lack of awareness about burn patient care outside the 
highly specialized and specific settings of Burn Centers, a mul-
tidisciplinary team should carry the complex management of 
severe burn victims. For instance, the care of severely burned 
patients is categorized in Switzerland as “Highly Specialized 
Medicine” (HSM).2,10–13 This HSM organization ensures the 
highest quality and excellence in healthcare, provided by an 
integrative and dynamic collaboration of multidisciplinary 
specialists. This strategy of multidisciplinary clinical care is 
also widely used worldwide.
In an open design, ICU physicians and nurses would be the 
primary care providers from a nonsurgical standpoint, along 
with plastic and pediatric surgeons as consultants (while on 
the reconstructive surgery floor, surgeons would be the pri-
mary care providers). Given the multidisciplinary character of 
care management for severely burned patients, team meetings 
should be held to discuss all patients of the Burn Center, and 
in addition to respective primary care providers, attendance 
to these meetings should routinely comprise physiotherapists, 
nutritionists, anesthesiologists, psychiatrists, and other 
medical consultants as needed. In our hospital, biologists 
and engineers from the research unit of the Plastic and 
Reconstructive Surgery service also attend these meetings, as 
they lead research projects and ensure proper implementation 
of GMP cellular production protocols. Likewise, scientists 
from the CPC (Cell Production Center, ie, GMP-accredited 
manufacturing facility of our hospital) provide updates about 
the amount of available cultured skin grafts and expected dates 
of delivery, in order to plan showers and surgeries accordingly.
Regarding postburn care, Burn Centers should sign collabo-
ration agreements with rehabilitation centers, in order to ensure 
a continuum of care for its burn patients after hospital dis-
charge, until social and professional reintegration is established. 
For instance, our Burn Center signed collaboration agreements 
with two external rehabilitation centers, namely the “Clinique 
Romande de Réadaptation” or CRR (Vaud, Switzerland) and 
Lavey-Medical SA (Valais, Switzerland), which reduces the 
costs considerably, as it will be shown hereafter.
Managing the Risks and Costs in the Organization of 
a Burn Center
Due to the naturally fluctuating burn patient ad-
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Figure 1. Illustration of a main Burn Unit located on the general ICU floor, with representation of an unconventional “open-space design” 
facilitating clinical and logistic workflows. Depicted locations comprise essentially the isolation box and regular rooms, the general ICU area, the 
main operating theater, and the hydrotherapy room, as well as other areas such as the reception desk, the technical room, the storage room, the 
meeting room, the office, and the waiting room. ICU, intensive care unit.
Table 1. Specificities and related advantages of an “open-design” Burn Center from an architectural and organizational perspec-
tive
Characteristic Advantages
Open main Burn Unit Facilitated clinical and logistic workflows
Merged adult and pediatric care Centralization of personnel resources, clinical competencies, and 
dedicated equipment
Isolation box with operating theater and hydrotherapy capacity Possibility to treat patients autonomously while maintaining isola-
tion, for protection of the patient and the Burn Unit
Dedicated operating theater in the Burn Unit Proximity with dedicated intensive care beds, limited transit dis-
tance, and high reaction capacity to emergencies
Burn Unit on main ICU floor Proximity of intensive care providers and equipment in case of 
emergency, and limited transit distance
In-house GMP manufacturing facility No dependency on external providers and direct control on 
procedures and quality
Isolators for cell therapy production chain Facilitated accreditation and relatively low overall costs of operation
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toward resource utilization optimization.14,15 As mentioned 
hereabove, a notable characteristic of our Burn Center 
structure is the open-space design, facilitating clinical 
and logistic workflows while reducing costs, since space 
and personnel are attributed interchangeably to burn and 
nonburn patients, as a function of burn patient admissions. 
For instance, general ICU patients or routine plastic sur-
gery patients are admitted to the Burn Center, when burn 
patients are scarce. These nonburn patients will occupy the 
same space and will be taken care of by the same personnel 
that take care of burn patients, when present. Programs 
that educate multidisciplinary staff for burn patient care are 
essential and result in increased commitment to the Burn 
Center.16 Despite its benefits, the open-space setup does 
not resemble many other Burn Center structures that we 
have had the privilege to visit over the years (ie, Canada, 
India, and Taiwan), which is why we advocate for such de-
sign as set forth in our guideline.
On the same line of optimized resource utilization, the 
operating room that is dedicated mainly for burn patients 
can be used for other surgical interventions: in our hospital, 
this room is occasionally used for organ retrieval for trans-
plantation purposes. In addition, both hydrotherapy and 
operating rooms should also be implicated in the treatment 
of severe cutaneous conditions such as Lyell and Stevens–
Johnson syndromes or necrotizing fasciitis, as these cases 
necessitate similar medical care as for burns. In addition, 
minimizing infectious complications (Figure 1, isolation 
box) results in controlled morbidity and mortality. This can 
be achieved via specific structural designs, workflows, and 
use of therapies proven to decrease complications and hos-
pital stays.17–21 Further information on infrastructure opti-
mization is discussed in the “Managing Risks and Costs of 
Cellular Therapies” section, namely for the manufacturing 
of cell therapies.
Finally, signing collaboration agreements with rehabilita-
tion centers allows to reduce the costs of hospitalizations; in 
our case, from around 1000 Swiss Francs (CHF) per day on 
the regular floor in our hospital to around 400 CHF per day 
at CRR and 200 CHF per day at Lavey-Medical SA.
STANDARDIZED CELL THERAPY 
INTEGRATION FOR SEVERE BURN 
PATIENTS
Worldwide efforts in specialized hospital centers have been 
made to develop and implement novel cell therapy approaches 
to fill the gaps and unmet needs in conventional surgical 
treatment of severe burns.22 Early surgical intervention and 
Tissue Engineering Products (TEPs) decrease morbidity and 
mortality of severely burned patients, as they allow for rapid 
wound coverage, thereby decreasing fluid loss and nosocomial 
infection risks.23–25 In addition, cell therapies promote epi-
thelialization of burn wounds as well as donor sites, thereby 
hastening the coverage process.22,26 Medico-economic 
analyses have demonstrated the efficiency of established cell 
therapy protocols, enabling reimbursement by basic health in-
surance, especially when the remaining amount of skin may 
not be enough for conventional skin grafting (ie, >50% TBSA 
burns in adults and >30% TBSA burns in children). We will 
detail in this section different cell therapies known for burns 
(Table 2), with a discussion on the optimization and the costs 
of an “in-house” model of cell therapy manufacturing.
Platelet-Rich Plasma
Autologous platelet-rich plasma (PRP) treatments are used 
in superficial burns and on split-thickness skin graft donor 
sites, with good overall results and high relative cost-effec-
tiveness.5,27,28 They are safe and their manufacturing process is 
easily standardized. Acute burn wounds generally necessitate 
1 ml of PRP preparation to treat surfaces of 100 to 150 cm2, 
while chronic wounds are more demanding, with an average 
of 1 ml preparation for 10 cm2 areas.
Autologous PRP preparations are obtained by a two-step 
differential centrifugation protocol applied to patient whole-
blood (ie, ~20  ml, sodium citrate-stabilized) and isolation 
of autologous thrombocytes in restricted plasma volumes 
(Figure 2). The resulting cell suspension (ie, 1–2 ml, concen-
trated 2–3-fold) is then reinjected or applied topically. This 
intervention stimulates tissue repair and modulates responses 
to injury, thereby enhancing wound healing. Autologous PRP 
Table 2. Overview of GMP cell therapies currently used in Burn Centers
Therapy Treatment Unit Definition Composition Lot Composition
Manufacture 
Timeframe
PRP 2 ml (5.0 × 108 ± 2.3 × 108 platelets) Autologous plasma and thrombocytes 1 syringe 2 h
CEA 75 cm2 sheet Stratified autologous cultured keratinocytes  
Vaseline gauze  
Traces of rinsing medium and feeder-layer 
fibroblasts
50 units 3–4 weeks
CDEA 75 cm2 sheet Stratified autologous cultured keratinocytes and 
fibroblasts  
Vaseline gauze  
Traces of rinsing medium and feeder-layer 
fibroblasts
20–40 units 6–8 weeks
PBB 108 cm2 construct (5.0 × 105 ± 0.5 × 105  
allogenic cells)
Human cultured progenitor dermal fibroblasts  
Equine collagen sheet  
Rinsing and incubation medium traces
2–50 units 18–72 h
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may be sprayed on the wounds in combination with fibrin 
sealant (eg, Artiss® from Baxter, Evicell® from Ethicon).
Cultured Epithelial Autografts and Keratinocyte 
Suspensions
Cultured epithelial autografts (CEAs) were originally devel-
oped in Brigham Hospital in Boston, USA,29 where successful 
patient treatments were published starting in the 1980s.30–32 
Extensive clinical data available today confirm the usefulness 
of CEAs in Burn Centers.33–37
CEAs are composed of autologous cultured and strat-
ified keratinocyte sheets (Figure 3). They are prepared 
from a healthy epidermal biopsy isolated from the patient 
(ie, <10  cm2, ideally from axillary or inguinal regions). 
Enzymatic digestion enables isolation of single-cell keratin-
ocyte suspensions, which are used for serial in vitro culture 
expansions on feeder layers (ie, murine fetal 3T3-J2 fibroblast 
cell line). After 3 weeks of expansion, resulting keratinocyte 
sheets (ie, stratified, six to eight layers with epidermal pheno-
type and differentiation) are then harvested and transferred 
to Vaseline-covered bandages, which are subsequently applied 
to deep partial-thickness burns and stapled in place. Around 
15 to 50 CEAs are usually prepared for each severe burn pa-
tient, and numbers are adapted according to wound size. 
Alternatively, expanded keratinocytes may be resuspended and 
applied in spray formulations based on wound type, topology, 
and urgency of treatment. This practice has been used period-
ically over the years when urgent clinical situations arose.5,38–40
Cultured Dermal–Epidermal Autografts
Cultured dermal–epidermal autografts (CDEAs) are an evo-
lution of CEAs and broaden the scope of clinical applications 
(Figure 4), as they comprise both autologous cultured 
keratinocytes and fibroblasts.41–44 They were developed and 
applied clinically since the 1990s, in deep partial- and full-
thickness burns specifically. The biphasic composition of 
CDEAs provides a relatively stronger layer for skin recon-
struction. The current clinical management strategy restricts 
their use to patients presenting over 70% TBSA burns, as re-
constructive efforts are highly time-consuming and allow for 
lengthy cell production delays. A  main advantage of these 
constructs is the relatively low induced retraction property, 
allowing for application in anatomical sites where skin retrac-
tion is to be avoided (eg, articulations, neck).
To obtain this type of construct, a full-thickness healthy 
skin biopsy is isolated from the patient and is differentially 
submitted to enzymatic and mechanical treatments in order to 
isolate the cell types of interest (Figure 5). After appropriate 
in vitro expansion and specific cell stimulation, resulting 
bicomponent cellular sheets are applied to the patient wounds 
in the same manner as CEAs. Comparative evaluations have 
shown that for deep wounds, CDEA constructs combined 
with commercial dermal substitutes provided relatively su-
perior clinical outcomes, with reconstructed skin presenting 
ameliorated functional mechanical properties than samples 
from the CEA group. Indeed, CDEAs were the only products 
able to promote effective re-epithelialization of Integra® or 
Matriderm® constructs. Despite high utility in wound cov-
erage and repair stimulation, both CEAs and CDEAs suffer 
from the inherent disadvantage of necessitating extensive 
manufacturing delays (ie, 3–4 and 6–8 weeks, respectively), 
due to cell culture procedures. Nevertheless, once the initial 
in vitro culture periods are over, new cultured autografts may 
be made available regularly by continuous production and 
cryopreservation of specific patient cells.
As reconstruction success has been limited to the epi-
dermis and dermis to date, it will be necessary to further as-
sociate hypodermis and specific cell types from this tissue to 
abovementioned routine methods to improve the quality of 
regenerated skin. The inclusion of adipose stem cell culture 
could be this next step of reconstruction.45
Allogenic Cell-Based Therapy: Progenitor Biological 
Bandages
Progenitor Biological Bandages (PBBs) were developed 
and introduced since the 2000s as customized and safe 
products.6,46,47 Due to their short manufacturing delays, PBBs 
provide a rapid wound coverage solution, without the need for 
skin grafts (Figure 6). They are currently classified as combined 
Advanced Therapy Medicinal Products (cATMP) under rel-
evant European legislation and as Standardized Transplants 
under Swiss legislation. PBBs allow bioactive wound coverage 
and healing, based on allogenic primary progenitor dermal 
fibroblasts formulated on a moldable bioresorbable equine 
collagen sponge.8 Primary progenitor dermal fibroblasts were 
isolated under a dedicated Transplantation Program and used 
to constitute tiered cryopreserved cell banks within GMP 
specifications.22
In addition to numerous technical and clinical advantages 
characterizing the robust progenitor cell source, clinical 
applications of PBBs have yielded promising results in par-
ticular for pediatric burn patients (Figure 7). In addition to 
rapid primary wound or donor site wound coverage, PBBs 
may lower pain, prepare wound beds for subsequent grafting 
when necessary, stimulate repair and regeneration, and mini-
mize scar tissue formation by moderating host tissue functions 
via growth factor and cytokine paracrine signaling pathways.22 
With regard to wound depth, PBBs are supposed to optimally 
stimulate spontaneous skin healing and minimize scaring 
of superficial zones, reduce the risk of edema and capillary 
thrombosis in intermediate zones, which in turn implies a re-
duction of the body area to be grafted, and prepare deeply 
affected zones for skin grafting.9 Notably, PBBs do not re-
quire stapling during clinical application, and are rapidly and 
naturally degraded without residual necrotic tissue forma-
tion. This results in an easy and relatively painless bandage 
exchange procedure.8
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Managing Risks and Costs of Cellular Therapies
Improvements of cellular therapy protocols may be attained 
through simplifying methods of manufacturing to reduce 
overall costs while the quality of the final product is guaranteed 
or even improved. Indeed, several cell therapy protocols are 
available to date at our institution following internal validated 
Standard Operating Procedures, with considerable efforts 
made toward compliance with local, national, and global 
quality rules and regulations. Hence, all products destined for 
clinical use (ie, in our hospital or sent abroad) are manufac-
tured in-house by the accredited and authorized CPC, under 
current Good Manufacturing Practices (cGMP) standards.
Our in-house GMP manufacturing workflows unconven-
tionally designed with all contact process steps carried out 
within a bioconfinement class A closed module and installed 
in class D production suites may be a cost-effective option 
(Figure 8). Contrasting with traditional open-system GMP 
infrastructures and equipment (ie, class A laminar flow hood 
in class B suites), this closed-system installation requires 
less overall maintenance, less personnel, and less cleaning 
procedures. The adoption of these closed-system GMP 
manufacturing chains also diminishes the frequency of product 
nonconformity. On the long run, these in-house dispositions 
allow for effective risk mitigation, control simplifications, 
and reduced overall manufacturing costs, for the following 
reasons: 1)  the Burn Center does not rely on the supply of 
an outsourced structure or company in order to provide cell 
therapies for their patients; 2) each closed class A module is 
designed and controlled in order to allow the manufacture of 
cell therapy products for different cell types in parallel, which 
is pivotal in the case of cell therapies for acute wounds such as 
burns; 3) several closed class A modules ensure a continuous 
supply of cell therapies even in the case of maintenance, as 
other modules are available for manufacture.
Furthermore, the cost-effectiveness of wound coverage 
products is multifactorial, as improved clinical outcomes may 
shorten hospital stays and reduce overall costs, despite the rela-
tively high individual product prices. As an example, a 24-hour 
stay in a Swiss Burn Center costs on average 4000 to 6000 
CHF per day, therefore it is estimated that a 50% TBSA burn 
patient costs in excess of 150,000 CHF, which may be put into 
perspective with the costs of commercial wound coverages (ie, 
3340 CHF for 1 m2 porcine cover, around 12,000 CHF for 
1 m2 human cadaveric skin substitute).1,2 These figures can 
Figure 3. Graphical schematization of cultured epithelial autograft (CEA) GMP manufacture. An epidermal biopsy of healthy skin is harvested 
from the patient and enzymatically dissociated (trypsin 0.1%, mechanical agitation at 37°C, filtration on 100 µm cell strainers). Confluent 3T3-J2 
murine fibroblasts are growth-arrested by adjunction of mitomycin C (4 µg/ml) and are used as feeder layers for coculture proliferation support. 
Keratinocytes are grown in culture medium composed of DMEM, HAM’s F12, FBS, l-glutamine, EGF, hydrocortisone, cholera toxin, penicillin–
streptomycin, insulin, and gentamycin. After expansion of sufficient keratinocyte populations (around 60% confluence), cells may be harvested 
in sheets for CEA preparation (dispase 0.25% treatment) or harvested (trypsin–EDTA, 0.05–0.01%) and suspended in cryopreservation medium 
(BIOFREEZE) and frozen for long-term storage. After incubation, cell sheets are rinsed with DMEM supplemented with penicillin–streptomycin. 
For transfer to the clinic, constructs are mechanically transferred and clipped onto Vaseline gauze (7.6 cm × 23 cm) and immersed in rinsing me-
dium supplemented with gentamycin. The different manufacturing steps result in a production delay of about 3 weeks for a given patient before 






/jbcr/advance-article/doi/10.1093/jbcr/irab080/6273217 by EPF Lausanne user on 17 June 2021
Journal of Burn Care & Research 
Volume XX, Number XX Chemali et al  7
furthermore be compared to the costs of PBBs, which amount 
to about 2550 CHF for 1 m2, constituting an additional ar-
gument for continued in-house manufacture and specific 
therapeutic use.
Continuous optimization and standardization of cellular 
therapy protocols are necessary to ensure safety and effec-
tiveness of final products.48 Such undertakings may comprise 
replacement of animal products in manufacturing processes, 
choice of therapeutic delivery systems allowing for shorter 
culture periods, or integration of ancillary autologous cellular 
components promoting product stability (eg, PRP).5,49
REGULATORY HURDLES AND SOLUTIONS 
FOR CELL THERAPIES IN HOSPITALS
Evolution of Regulatory Framework of Cell Therapies
The abovementioned cell therapies currently face potentially 
jeopardizing challenges on the policy front in Europe.50–55 
Indeed, evolution of requirements for use of ATMPs have 
brought market authorizations to a stall. Conjugation of 
cGMP manufacture and extended regulatory submission 
steps bear stifling costs for many key sponsors interested in 
bringing novel and salutary regenerative medicine products 
to patient bedsides.50,56,57 This is exemplified at the level of 
University Hospitals actively resorting to cell therapies, for 
which industry-destined GMP guidelines are being enforced 
and result in pharaonic manufacture costs. This problem-
atic resonates at multiple institutional levels and has opened 
wide debate around strategic operations of Burn Centers in 
particular, as many well-established hospital practices were 
denounced as illegal with respect to European directives or 
national regulations. According to these regulations, the 
hospital must hold, on the one hand, a manufacturing au-
thorization specific to the concerned therapeutic products, 
and on the other hand, a market authorization (AMM) 
even to apply the therapeutic products to its own patients. 
Figure 4. Graphical schematization of cultured dermal–epidermal autograft (CDEA) GMP manufacture. A full-thickness biopsy of healthy skin 
is harvested from the patient and submitted to thermolysin treatment (1 hour at 4°C in 0.05% thermolysin) before parallel enzymatic (trypsin–
EDTA) and mechanical dissociation (trituration and explant method). Patient fibroblasts are culture expanded and may also be cryopreserved 
or cocultured for CDEA preparation, with an intermediary stimulation using vitamin C (100 µl of 20 mM solution, for stimulation of collagen 
production) in the second case. Coculture of both patient cell types results in rapid formation (~7 days) of stratified cell sheets to be harvested for 
CDEA preparation. Culture vessels are opened or thermally cut to extract the cell sheets. The different manufacturing steps result in a production 
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Although the necessity of a manufacturing authorization 
may be reasonable in terms of patient safety, an AMM is not 
justified in the case where products to be administered are 
manufactured by the hospital laboratory/pharmacy specif-
ically for their own patients. Therefore, hampering effects 
due to regulatory frameworks and implied costs has driven 
public institutions to seek specific policy exceptions enabling 
suitable and continued use of crucial personalized therapies 
(Table 3).56–59
In the specific context of burn patient care, it is important 
that the adequate choice of treatment, potentially including 
cellular therapy, is retained by the primary caregivers, as prag-
matic, rapid, and effective wound management is often essen-
tial for patient survival. While maintaining the most stringent 
quality standards and requirements for the hospital manufac-
ture of cell therapies, straightforward regulatory frameworks 
are paramount in assuring safe and effective care provision 
to burn patients.51,52,56,60 For instance, in Switzerland, cell 
therapy manufacture for therapeutic use must submit to 
cGMP standards and comply with dispositions and ordinances 
of the federal therapeutic products legislation (ie, Federal Act 
on Medicinal Products and Medical Devices, Therapeutic 
Products Act, TPA, SR 812.21 and related Ordinances).
Practically, new European Directives (ie, 2001/83/EC) 
and Regulations (ie, 726/2004, with the amended Regulation 
1394/2007) have been implemented and interpreted in variable 
manners throughout Europe over the last years.61–63 Coupled 
to these frameworks, the renewed Swiss Transplantation 
Legislation has led to complex pathways to be implemented, 
which could potentially adversely affect severe burn patients 
and appropriate clinical care decisions. Indeed, before 2007, all 
new cell therapy techniques were presented before State Ethics 
Committees and were registered with the Department of Public 
Health once approved. Since the abovementioned regulatory 
shifts, all therapies that comprise cell culture techniques are 
by legal definition considered to be Standardized Transplant 
Products, as a consequence of the standardized in vitro proc-
essing of the biological products.4 As a result, cell therapies such 
as CEA/CDEAs or PBBs are to be regulated similarly to clas-
sical or biological drugs for all development and therapeutic 
Figure 5. Graphical illustration of various manufacturing steps of cultured skin autograft (CEA or CDEA) manufacture. (A) A full-thickness 10 
sq cm2 biopsy is procured. (B) Patient dermal fragments are minced and cell cultures are initiated using seeding for keratinocytes or an explant 
method for fibroblasts. (C) Cells are culture expanded and harvested with trypsin–EDTA (0.05–0.01%). (D) Culture flasks are cut for stratified 
cell sheet harvest. (E and F) Cell sheets are carefully removed from the culture vessels. (G) Cell sheets are adjusted on adequate Vaseline gauze to 
form CEAs or CDEAs. (H) Sheets are put into square flasks contain a small quantity of medium and conditioned into a hermetic box (as secondary 
containment) for transport. (I) CEAs or CDEAs are processed for clinical application in the operating theater. CDEA, cultured dermal–epidermal 
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use considerations (Article 49 of the Transplantation Act, 
Therapeutic Products Act, and Medicinal Products Licensing 
Ordinance MPLO, SR 812.212.1).64,65 The authorization 
requirements for transplant products have thus been aligned 
more closely to those for medicinal products, even if adjustments 
have been admitted to be necessary according to the specific na-
ture of TPs (Swissmedic Information Sheet I-313.AA.01-A15e, 
2019). Direct and specific outcomes of such frameworks imply 
that University Hospitals, despite their general interest mission, 
are held to the same standards as pharmaceutical industries, 
which must seek exploitation authorizations for manufacturing 
cell-based products, licenses to conduct clinical trials, and full 
authorizations for market approval (AMM) as for commercial 
drugs.65 Furthermore, regulation changes imply that hospital 
infrastructure must follow cGMP standards for production, 
Quality Assurance, and Quality Control of all processes for use 
Figure 6. Graphical schematization of progenitor cell type isolation, tiered cell banking, and Progenitor Biological Bandage (PBB) GMP manu-
facture. (A) A small (<2 cm2) fetal skin biopsy is processed using an explant method to establish a primary progenitor cell type (dermal fibroblasts). 
Cells are culture expanded and cryopreserved to constitute a Parental Cell Bank (PCB). This procedure is carried out only once, as the tiered 
banking system requires only one organ donation. (B) Using materials from the PCB, a culture expansion is conducted to establish a cryopreserved 
Master Cell Bank (MCB). (C) Using materials from the MCB, serial culture expansions are conducted to establish cryopreserved Working Cell 
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in the Burn Center. However, not many hospitals worldwide 
possess the necessary infrastructure, specialists, and financing 
to maintain these requirements following the letter of the 
new laws.
Along with the availability of such dedicated manufacturing 
platforms, the new product classification issues remain, which 
is problematic for protocols and therapies which have been 
safely and routinely used for decades.51,53 Indeed, as ATMPs 
may be classified as standardized transplants (ie, substantial 
modifications of patient biological materials), they are nor-
mally required to be evaluated within standard clinical trials, 
notwithstanding extensive scientific and clinical hindsight 
of over 30  years. Pragmatically, developing a randomized 
controlled clinical trial for treating severe burn patients could 
present a significant ethical dilemma, as cell therapies such as 
discussed herein are firstly implemented to save lives in the race 
for sufficient burn wound coverage. Therefore, for these types 
of cell therapies, hospital exemptions, compassionate use, or 
resort to Hospital Magistral Preparation (HMP) frameworks 
would be most appropriate pathways circumventing regula-
tory deadlocks.60
Hospital Exemptions
Provided that hospitals possess or work with adequate ac-
credited GMP infrastructures, it would be most logical 
to implement hospital exemptions in order to offer safe 
cell therapies for burn patient betterment.56 According to 
Article 28 of the European Regulation 1394/2007 revi-
sion, the “Hospital Exemption is applied to any ATMP which 
Figure 7. Photographic illustration of pediatric thermal burn wound (scalding injury) evolution after clinical application of PBBs. Second degree 
superficial and deep burns covered 12% of the TBSA. (A) Aspect of the burns after thorough cleaning and washing. (B) Application of PBBs the 
next day. (C) Aspect of the burns 48 hours after treatment initiation. (D) Aspect of the burns 4 days after treatment initiation. (E and F) Aspect of 
the burns 6 weeks after treatment initiation. Full structural and functional recovery were attained, without formation of scar tissue. PBB, Progenitor 
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is i. Not intended to be placed on the market; ii. Prepared on a 
non-routine basis; iii. Not within an industrialized manner; 
iv. Prepared as a custom-made product for an individual pa-
tient.” 63 Unfortunately, the European directive may have 
multiple interpretations for what is considered “non-routine 
basis,” “industrial process,” or “custom-made,” preventing 
the adoption of a consensus around hospital exemptions. 
In Switzerland, the situation is even more restrictive, be-
cause such exemptions are currently admitted under specific 
conditions for medicines, but are excluded for standardized 
transplants [Article 2 alinea 2 of  the Therapeutic Products 
Ordinance (TPO), SR 812.212.21].65
Figure 8. Photographic representation of the in-house Cell Production Center GMP production platform with isolator manufacturing chains. (A) 
Overview of the main production unit. (B) Handling of the cell cultures in the isolator workspace, before reincubation in the integrated controlled 
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Compassionate Use
Article 37 of the Declaration of Helsinki specifies: “In the 
treatment of an individual patient, where proven interventions 
do not exist or other known interventions have been ineffective, 
the physician, after seeking expert advice, with informed con-
sent from the patient or a legally authorized representative, may 
use an unproven intervention if in the physician’s judgement 
it offers hope of saving life, reestablishing health or alleviating 
suffering. This intervention should subsequently be made the ob-
ject of research, designed to evaluate its safety and efficacy. In 
all cases, new information must be recorded and, where appro-
priate, made publicly available”.67
Therefore, in the absence of effective or available ther-
apeutic alternatives, an unauthorized TEP could ethically 
be used by attending clinicians, albeit under their own ex-
tended responsibility and legal exposure, as the warranted 
interventions defined in the Declaration may conflict with 
superseding local legal bases. Applicability of compassionate 
use for CEAs is additionally undermined by the undeniability 
of gathered clinical proof and the routine manufacture during 
several decades. Despite the fact that compassionate use is 
not provided as such by the Swiss legislation, hospitals may 
be allowed to prescribe unauthorized TEPs under certain 
conditions, if great therapeutic benefit is expected for the 
concerned patients [Articles 35–37, Therapeutic Products 
Ordinance (TPO), SR 812.212.21].
Hospital Magistral Preparations and Officinal 
Preparations
HMPs may constitute an alternative option which may re-
spect both existing regulatory frameworks and the depend-
ency of severe burn patients to rapid access to innovative 
therapies.60 As already mentioned, Switzerland foresees addi-
tional conditions for the HMP’s authorization exemption, in 
particular that the Pharmacopeia or another recognized drug 
formulary mentions the active substance (Article 37 § 1 letter 
d, TPO). HMPs (ie, compounded prescription drug products 
in the United States) are defined as products prepared, on 
demand or serially, in the pharmacy under the supervision of 
an authorized pharmacist, following a medical prescription, 
for an individual patient or a determined group of patients, 
according to scientific standards and technical specifications 
of pharmaceutical art (European Directive 2001/83/EC, 
Article 3, also defined by Article 9 § 2 letter a, TPA).61,64
Officinal preparations are similar to magistral preparations, 
but require that the pharmacist follows a recognized formula 
or monograph. Therefore, in alignment with recent work on 
bacteriophages and definitions of novel Active Pharmaceutical 
Ingredients, it is of great current interest to establish general 
or specific ATMP monographs to be adequately approved and 
implemented in specific compendia, allowing standardized 
preparation of TEPs for specific clinical indications and under 
the responsibility of the pharmacist and the prescriber. These 
have to be considered under GMP requirements, following a 
medical prescription and for a specific patient of the institution.60
In addition, with the adopted regulatory classifications and 
for the particular case of severe burn victims in need of salutary 
therapeutic interventions, appropriate clinical trials for cell 
therapies should be integrated with recruitment of patients 
that are not in life-threatening situations (ie, implemented 
for lower TBSA burns). This concerns potential commercial 
product development around autologous or allogenic cellular 
therapies, whereas an actual final product is fully developed 
for a specific clinical indication.
CONCLUSIONS
A growing synergistic collaboration of various professionals 
gravitating around burn care is of paramount importance, 
as it bears significant impact on morbidity, mortality, and 
optimized health capital restoration. Nevertheless, specific 
considerations for risk and cost management are crucial for 
Table 3. Possible regulatory pathways to maintain use of cell therapies in University Hospitals and Burn Centers for hospitalized 
patients
Regulatory Pathway Discussion Responsibility Bearing
ATMP-drug type dossier 
submission
Extremely costly and stringent regulatory requirements  
Requires subcontracting to CMO  
Mitigated interest by pharmaceutical industry
Clinician  
Manufacturer
Compassionate use  
(Helsinki declaration)




Hospital exemptions Restricted to products not intended to be marketed, prepared on a nonroutine 




Orphan drugs Produced for diagnosis, prevention, or treatment of a life-threatening disease or 






Products manufactured, on demand or serially, by an authorized pharmacy fol-
lowing a medical prescription and intended for the treatment of a determined 





Products manufactured, on demand or serially, by an authorized pharmacy fol-
lowing a recognized formula or monograph and to be used for treatment of 
the institution’s own patients
Clinician  
Pharmacist
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sustainability in burn care. These comprise specific choices 
of infrastructure and organization, technical and scientific 
aspects of cell therapy production, and clinical integration in 
modern regulatory frameworks.
Due to the naturally fluctuating burn patient admission 
rates, Burn Centers are pressured to optimize the use of 
their resources. Thus, an open-space design may be a good 
option to optimize the allocation of space and personnel. 
Collaboration agreements with rehabilitation centers en-
sure a continuum of postburn care and further reduce the 
costs of hospitalizations. In-house GMP manufacturing 
can also be designed unconventionally and cost-effectively 
within closed-system installations instead of the traditional 
open-system infrastructures, thereby allowing for control 
simplifications, effective risk mitigation, and reduced overall 
manufacturing costs. The cost-effectiveness of wound 
coverage products is multifactorial, as improved clinical 
outcomes may shorten hospital stays and reduce overall 
costs, despite the relatively high individual product prices.
Continuous optimization and standardization of cel-
lular therapy protocols contribute in simplifying methods of 
manufacturing and delivery to the patient, while reducing 
overall healthcare costs. To this day, the highest modifiable 
risk to vulnerable burn patients resides in the regulatory 
turmoil introduced by literal interpretations of European 
legislations by local regulators, thus in a market where public 
hospitals are being regarded as commercial pharmaceutical 
industries. Compromise should clearly not be made with re-
gard to quality standards for clinical product manufacture. 
However, current medical reality and the dire need of severe 
burn patients should prompt consensual establishment of a 
modus vivendi within public healthcare structures regarding 
historically used cell therapy interventions. Therein, appro-
priate product classification solutions should be implemented, 
guaranteeing compliance with the national and international 
regulatory landscape.
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